drugset
drugset / Trial / NCT00760539

Safety and Efficacy of Travoprost/Timolol BAC-free

NCT00760539 ↗

Phase 3 Completed 87 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension. This global study will be conducted in the US (C-07-64, NCT00672997) and Japan (C-08-08, NCT00760539).

Timeline

Start
2008-06
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Travoprost 0.004%/Timolol 0.5% ophthalmic solution Unknown — Other

Indications

ocular hypertension open-angle glaucoma